Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, randomized controlled trial. Patients with stable angina
pectoris without use of dual antiplatelet therapy or anticoagulation therapy scheduled for
coronary artery bypass grafting (CABG) at Karolinska University Hospital in Stockholm, Sweden
will be eligible.
This study investigates in patients having undergone CABG whether increasing the dose or the
frequency of acetylsalicylic acid (ASA) treatment improves the efficacy of ASA regarding
platelet inhibition compared to the standard dosing for cardiovascular prevention (75 mg once
daily) in the first three months after surgery. Patients will be randomly assigned to
postoperative ASA dose 75mg once daily, 75mg twice daily or 160 mg once daily. The study dose
ASA will be started at hospital discharge and continued of three months. Blood samples for
serum thromboxane B2 (TxB2) and other analyses will be taken before surgery, before
discharge, and after one and three months. All available data will be collected
prospectively. Informed consent will be obtained from patients meeting the inclusion criteria
before the initiation of any study-specific procedures.